Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)

Sare Verstockt(KU Leuven), Séverine Vermeire(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven)

Expert Opinion on Therapeutic Targets

October 6, 2019

10.1080/14728222.2019.1677608

Cited by 57

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

|Nature Genetics|2008|2.6k

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

|Journal of Crohn s and Colitis|2018|1.8k

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

|Journal of Crohn s and Colitis|2019|1.4k